BR112022007219A2 - Sequências de fragmento de anticorpo clec12a e métodos - Google Patents
Sequências de fragmento de anticorpo clec12a e métodosInfo
- Publication number
- BR112022007219A2 BR112022007219A2 BR112022007219A BR112022007219A BR112022007219A2 BR 112022007219 A2 BR112022007219 A2 BR 112022007219A2 BR 112022007219 A BR112022007219 A BR 112022007219A BR 112022007219 A BR112022007219 A BR 112022007219A BR 112022007219 A2 BR112022007219 A2 BR 112022007219A2
- Authority
- BR
- Brazil
- Prior art keywords
- clec12a
- coupler molecule
- molecule
- killer
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916340P | 2019-10-17 | 2019-10-17 | |
| PCT/US2020/055468 WO2021076545A1 (en) | 2019-10-17 | 2020-10-14 | Clec12a antibody fragment sequences and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022007219A2 true BR112022007219A2 (pt) | 2022-07-05 |
Family
ID=75538859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022007219A BR112022007219A2 (pt) | 2019-10-17 | 2020-10-14 | Sequências de fragmento de anticorpo clec12a e métodos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240117053A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4045540A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7796414B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220083760A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114929745B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020368354B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022007219A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3158111A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292238A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021076545A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021268340A1 (en) * | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| CN115850476B (zh) * | 2022-08-09 | 2023-09-05 | 合源康华医药科技(北京)有限公司 | 一种cll1抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8536310B2 (en) * | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| EP2245153A4 (en) * | 2008-02-13 | 2011-06-22 | Dyax Corp | IMPROVED METHODS FOR PRODUCING SPECIFIC BINDING SAVINGS |
| JP2013508308A (ja) * | 2009-10-23 | 2013-03-07 | ガーバン インスティテュート オブ メディカル リサーチ | 修飾可変ドメイン分子、ならびにその産生および使用方法 |
| BR112015006824A2 (pt) * | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| CN103467599B (zh) * | 2013-09-27 | 2015-06-17 | 中国农业科学院兰州兽医研究所 | 双峰驼源抗猪瘟兔化弱毒疫苗株e2抗原重链抗体vhh和用途 |
| EP3529268B1 (en) * | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| MX2019012953A (es) * | 2017-05-02 | 2020-02-12 | Alligator Bioscience Ab | Anticuerpo biespecifico contra ox40 y ctla-4. |
| WO2019108065A1 (en) * | 2017-12-01 | 2019-06-06 | Merus N.V. | Use of bispecific antibody and il-15 for combination therapy |
| WO2019118918A1 (en) * | 2017-12-15 | 2019-06-20 | Aleta Biotherapeutics Inc. | Cd19 variants |
| US11951129B2 (en) * | 2018-01-09 | 2024-04-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compositions and methods for targeting CLEC12A-expressing cancers |
-
2020
- 2020-10-14 JP JP2022522867A patent/JP7796414B2/ja active Active
- 2020-10-14 EP EP20877981.9A patent/EP4045540A4/en active Pending
- 2020-10-14 AU AU2020368354A patent/AU2020368354B2/en active Active
- 2020-10-14 US US17/768,793 patent/US20240117053A1/en active Pending
- 2020-10-14 CN CN202080087719.7A patent/CN114929745B/zh active Active
- 2020-10-14 CA CA3158111A patent/CA3158111A1/en active Pending
- 2020-10-14 WO PCT/US2020/055468 patent/WO2021076545A1/en not_active Ceased
- 2020-10-14 KR KR1020227016032A patent/KR20220083760A/ko active Pending
- 2020-10-14 BR BR112022007219A patent/BR112022007219A2/pt unknown
-
2022
- 2022-04-13 IL IL292238A patent/IL292238A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220083760A (ko) | 2022-06-20 |
| EP4045540A1 (en) | 2022-08-24 |
| JP7796414B2 (ja) | 2026-01-09 |
| CA3158111A1 (en) | 2021-04-22 |
| CN114929745B (zh) | 2025-11-18 |
| AU2020368354A1 (en) | 2022-05-12 |
| US20240117053A1 (en) | 2024-04-11 |
| WO2021076545A1 (en) | 2021-04-22 |
| JP2022553940A (ja) | 2022-12-27 |
| EP4045540A4 (en) | 2023-11-08 |
| AU2020368354B2 (en) | 2026-08-13 |
| IL292238A (en) | 2022-06-01 |
| CN114929745A (zh) | 2022-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200839A1 (es) | Anticuerpos anti-cd137 | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| CO6180445A2 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
| AR111207A1 (es) | Anticuerpos anti-lag3 | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| AR071510A1 (es) | Anticuerpos anti- factor d humanizados y sus usos | |
| PE20121360A1 (es) | Anticuerpos neutralizadores contra el receptor de prolactina | |
| PE20191436A1 (es) | Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| AR073978A1 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4-humano | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| BR0306979A (pt) | Polipeptìdeo isolado, proteìna de fusão, molécula isolada de polinucleotìdeo, vetor de expressão, célula cultivada, anticorpo ou fragmento de anticorpo, e, métodos para produzir uma proteìna, para produzir um anticorpo, para estimular uma resposta imune em um mamìfero, para expandir células hematopoiéticas e progenitores de células hematopoiéticas, para detectar a presença de rna zcytor17lig e de zcytor17lig em uma amostra biológica, para matar cérlulas cancerìgenas, para inibir a proliferação induzida por zcytor17lig ou diferenciação de células hematopoiéticas e progenitoras de células hematopoiéticas, para reduzir a inflamação induzida por zcytor17lig para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero acometido por uma doença inflamatória e para detectar inflamação em um paciente | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20211498A1 (es) | Anticuerpos dirigidos contra il-11 | |
| CY1123160T1 (el) | Αποκαρβοξυλαση γλουταμικου οξεος (gad) για χρηση στην αγωγη αυτοανοσης παθησης | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| Aranburu et al. | Age‐associated B cells expanded in autoimmune mice are memory cells sharing H‐CDR3‐selected repertoires | |
| AR121921A1 (es) | Composiciones y métodos de tratamiento del cáncer con receptores de antígeno quimérico | |
| PE20211497A1 (es) | Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso | |
| RU2015115399A (ru) | Антигены, ассоциированные с воспалительным заболеванием кишечника | |
| PE20220570A1 (es) | Anticuerpo anti-epha4 humano |